newsfilter
← Latest News
GlobeNewswire·

Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates

Advancing abdakibart toward a registrational Phase 3 program in hidradenitis suppurativa, with initiation planned for the first half of 2027Advancing AVTX-010, a next-generation, long-acting anti-IL-1β antibody, toward